Şirket yükleniyor
Just reported
Q3 2026 results
From GeneDx's results release of 9 Kasım 2026; its quarterly report has since been filed.
Revenue
Actual
$123,1M
+%5,4 y/y
+%7,6 q/qGuided
$123M
midpoint
Within guide+%0,1EPS, GAAP
Actual
-$0,41
Guided
—
No guide given
Operating income, GAAP
Actual
-$10,4M
Guided
—
No guide given
Company outlook
Q4 2026
- Revenue$135M+%12 y/y First given
Full year 2026
- Revenue$475M – $490M+%13 y/y Unchanged
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes GeneDx is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Diagnostics and Research
Graded A or B and worth $2B or more: A first, then the largest.
TMOThermo Fisher Scientific Inc.$259,4BA+
IDXXIdexx Laboratories Inc.$55,5BA+
IQVIQVIA Holdings Inc.$43,7BA
ILMNIllumina, Inc.$31,3BA+
LHLabcorp Holdings Inc.$30,1BA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 Eki 2026CBGraded C, now B
MCKMckesson Corporation4 Kas 2026BAGraded B, now A
CVSCVS Health Corp4 Kas 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 Kas 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 Eki 2026CAGraded C, now A
GeneDx Holdings Corp. şirketinin ABD Menkul Kıymetler ve Borsa Komisyonu’na (SEC) sunduğu kendi belgelerinden kuruldu. Rakamlar bildirildiği gibidir; hisse başına geçmiş bugünkü hisse tabanına göre yeniden hesaplanmıştır. Bu bir işletmeyi anlatır — yatırım tavsiyesi değildir ve alma ya da satma önerisi değildir.
